Lamivudine

Antiviral Agents
Effects of Maraviroc versus Efavirenz in Combination with Zidovudine-Lamivudine on the CD4/CD8 Ratio in Treatment-Naive HIV-Infected Individuals
Sergio Serrano-Villar, Giorgia Caruana, Alexander Zlotnik, José A. Pérez-Molina, Santiago Moreno
Antiviral Agents
Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors
Elena Lomonosova, Adam Zlotnick, John E. Tavis
Pharmacology
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding
Frantz Foissac, Jörn Blume, Jean-Marc Tréluyer, Thorkild Tylleskär, Chipepo Kankasa, Nicolas Meda, James K. Tumwine, Mandisa Singata-Madliki, Kim Harper, Silvia M. Illamola, Naïm Bouazza, Nicolas Nagot, Philippe Van de Perre, Stéphane Blanche, Déborah Hirt
and for the ANRS 12174 Trial Group
Pharmacology
Importance of Serum Concentration of Adefovir for Lamivudine-Adefovir Combination Therapy in Patients with Lamivudine-Resistant Chronic Hepatitis B
Fukiko Mitsui, Masataka Tsuge, Takashi Kimura, Shosuke Kitamura, Hiromi Abe, Hiromi Saneto, Tomokazu Kawaoka, Daiki Miki, Tsuyoshi Hatakeyama, Nobuhiko Hiraga, Michio Imamura, Yoshiiku Kawakami, Hiroshi Aikata, Shoichi Takahashi, C. Nelson Hayes, Harue Igarashi, Kentaro Morimoto, Masao Shimizu, Kazuaki Chayama
Antiviral Agents
Is the Recommended Once-Daily Dose of Lamivudine Optimal in West African HIV-Infected Children?
Naïm Bouazza, Déborah Hirt, Christophe Bardin, Serge Diagbouga, Boubacar Nacro, Hervé Hien, Emmanuelle Zoure, François Rouet, Adama Ouiminga, Stephane Blanche, Philippe Van De Perre, Jean-Marc Tréluyer, Philippe Msellati, Saik Urien
Antiviral Agents
Randomized Controlled Study Investigating Viral Suppression and Serological Response following Pre-S1/Pre-S2/S Vaccine Therapy Combined with Lamivudine Treatment in HBeAg-Positive Patients with Chronic Hepatitis B
Pham Thi Le Hoa, Nguyen Tien Huy, Le The Thu, Cao Ngoc Nga, Kazuhiko Nakao, Katsumi Eguchi, Nguyen Huu Chi, Bui Huu Hoang, Kenji Hirayama
Antiviral Agents
Protease Inhibitor Resistance Analysis in the MONARK Trial Comparing First-Line Lopinavir-Ritonavir Monotherapy to Lopinavir-Ritonavir plus Zidovudine and Lamivudine Triple Therapy
Constance Delaugerre, Philippe Flandre, Marie Laure Chaix, Jade Ghosn, François Raffi, Pierre Dellamonica, H. Jaeger, D. Shürmann, Isabelle Cohen-Codar, Philippe Ngo Van, Michael Norton, Anne-Marie Taburet, Jean-François Delfraissy, Christine Rouzioux
and for the MONARK Study Group
Antiviral Agents
Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
James F. Demarest, Heather Amrine-Madsen, David M. Irlbeck, Kathryn M. Kitrinos
and on behalf of the CCR102881 Clinical Study Team
Antiviral Agents
High Levels of Zidovudine (AZT) and Its Intracellular Phosphate Metabolites in AZT- and AZT-Lamivudine-Treated Newborns of Human Immunodeficiency Virus-Infected Mothers
Lucie Durand-Gasselin, Alain Pruvost, Axelle Dehée, Genevieve Vaudre, Marie-Dominique Tabone, Jacques Grassi, Guy Leverger, Antoine Garbarg-Chenon, Henri Bénech, Catherine Dollfus
Mechanisms of Resistance
Mechanisms by Which the G333D Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Facilitates Dual Resistance to Zidovudine and Lamivudine
Shannon Zelina, Chih-Wei Sheen, Jessica Radzio, John W. Mellors, Nicolas Sluis-Cremer

Main menu

User menu

Search

Lamivudine

Pages